Amarin Corp Plcuk (AMRN) Return on Capital Employed (2011 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Return on Capital Employed of 8.66% for Q2 2026, up 1449.0% year-over-year from 0.56% in Q2 2025, and up 7.39% quarter-over-quarter from 9.35% in Q1 2026.
Amarin Corp Plcuk (AMRN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Return on Capital Employed for 16 consecutive years, with 8.66% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed rose 1449.0% year-over-year to 8.66%; the TTM figure through Jun 2026 stood at 8.66% (up 1449.0% YoY), while the FY2025 annual figure was 10.37%, up 549.0% from the prior year.
- Return on Capital Employed improved to 8.66% in Q2 2026 per AMRN's latest filing, from 9.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2.29% in Q1 2022 and bottomed at 23.15% in Q2 2025.
- Historically, Return on Capital Employed has averaged 12.64% across 5 years, with a median of 12.0% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 1814 bps — and 2026, when it surged 1449 bps.
- Amarin Corp Plc\Uk's Return on Capital Employed stood at 16.6% in 2022, then climbed by 29 bps to 11.73% in 2023, then slumped by 45 bps to 17.06% in 2024, then soared by 38 bps to 10.66% in 2025, then grew by 19 bps to 8.66% in 2026.
- Business Quant data shows AMRN's Return on Capital Employed at 8.66% in Q2 2026, 9.35% in Q1 2026, and 10.66% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -8.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.66% |
| Mar 31, 2026 | -9.35% |
| Dec 31, 2025 | -10.66% |
| Sep 30, 2025 | -19.96% |
| Jun 30, 2025 | -23.15% |
| Mar 31, 2025 | -18.69% |
| Dec 31, 2024 | -17.06% |
| Sep 30, 2024 | -7.69% |
| Jun 30, 2024 | -7.16% |
| Mar 31, 2024 | -10.88% |
| Dec 31, 2023 | -11.73% |
| Sep 30, 2023 | -12.41% |
| Jun 30, 2023 | -9.51% |
| Mar 31, 2023 | -15.09% |
| Dec 31, 2022 | -16.60% |
| Sep 30, 2022 | -12.27% |
| Jun 30, 2022 | -14.39% |
| Mar 31, 2022 | -2.29% |
| Dec 31, 2021 | 1.54% |
| Sep 30, 2021 | 0.23% |